Partner, Chief Executive Officer
Carl Hull is a proven industry leader, with over 30 years of experience in the diagnostics and life sciences industries. Having spent 14 years at Abbott Laboratories in a variety of sales, marketing and general management positions, Carl then took on leadership roles at Ventana Medical Systems (acquired by Roche), Applied Imaging (now part of Danaher) and Applied Biosystems (now part of Thermo Fisher Scientific).
in 2007, Carl was recruited to join Gen-Probe as part of a board-directed succession plan for the CEO. Carl took over as CEO in 2009 and focused the strategy of the company to take full advantage of its core molecular diagnostics and automation strengths. By introducing highly innovative molecular diagnostic systems such as the PANTHER® and novel screening assays such as APTIMA® HPV, the company extended its recognized leadership position in the most rapidly growing segment of diagnostics. During Carl's tenure, the value of Gen-Probe doubled, creating nearly $2 billion in value for shareholders and culminating in a successful sale of the business in 2012 to Hologic, a leading company focused on helping women everywhere lead longer, healthier lives.
Carl holds a BA from The Johns Hopkins University and an MBA from the University of Chicago. He can be contacted at: firstname.lastname@example.org or 858-337-3593.
Eric Tardif began his career as an investment banker, initially in the mergers & acquisitions group of Merrill Lynch, then with Piper Jaffray and finally with Morgan Stanley. Throughout his banking career, Eric centered his attention on medical device companies, with a particular focus on the life sciences tools and diagnostics segments. Eric left Morgan Stanley as a managing director in 2009 to join Gen-Probe.
At Gen-Probe, Eric led the Corporate Development and Corporate Strategy functions, focusing with Carl on reshaping and executing the company's new strategy while effecting acqusitions, divestitures and licensing transactions. Eric also took on various operating roles, overseeing sales, marketing, operations, research & development and quality & regulatory functions at various times. Eric played a central role in effecting the sale of Gen-Probe to Hologic. Following the transcation, Eric was promoted to lead corporate strategy for the Hologic. Eric left Hologic in 2013.
Eric holds a BA from Bishop's University, an MBA from the University of British Columbia and a Master of Sciences in Finance from Boston College. Eric is a CFA Charterholder. Eric can be reached at email@example.com and 650-575-0765.
Vice President, Product Development and Operations
Tony currently serves as Maravai Life Sciences’ Vice President, Product Development and Operations. Prior to joining Maravai Life Sciences, Tony was Proprietor of ALH Consulting, LLC specializing in the implementation of product development programs, Vice President of R&D at BioArray Solutions, Director of Ventana Medical Systems Molecular Discovery Division, Vice President of R&D and Chief Scientific Officer at Centocor Diagnostics, Vice President of R&D and interim Vice President of Operations at Ventana Medical Systems. Prior to entering the private sector, Tony was a Research Assistant Professor of Pathology and member of Academic Pathology Associates at the University of Cincinnati Medical School. Tony holds an M.S. degree in Biophysics and Genetics from the University of Colorado Health Sciences Center and a BS degree in General Science from the University of Portland. Tony can reached at firstname.lastname@example.org.
Vice President, Chief Financial Officer
Mr. Herde joins Maravai from Sorrento Therapeutics, a publicly-traded biopharmaceutical company, where he was most recently Executive Vice President and Chief Financial Officer. Prior to Sorrento Therapeutics, Mr. Herde served as the Vice President of the Global Blood Screening business at Hologic, where he managed a multinational business providing molecular diagnostic solutions to improve blood safety in conjunction with the company’s strategic partners at Grifols and Novartis. Mr. Herde was also Vice President, Finance and Corporate Controller for Gen-Probe, the leading independent molecular diagnostics company, prior to its acquisition by Hologic in 2012.
Vice President, Chief Commercial Officer
David currently serves as Maravai Life Sciences’ Chief Commercial Officer. In that capacity, David is responsible for all marketing, sales, product, commercial strategy, service, and support for the company’s portfolio. Previously, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Prior to Affymetrix, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene, and The Linus Group. David is a Phi Beta Kappa graduate of Rutgers University where he specialized in biochemistry and was a Henry Rutgers Scholar. David can be reached at email@example.com.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.